126 results
DEFA14A
ACGN
Aceragen Inc
11 Jul 23
Additional proxy soliciting materials
5:07pm
, interference, reexamination, opposition, post-grant review, or investigation pending or, to the knowledge of Aceragen, threatened against Aceragen or any … , proceeding or investigation by Aceragen pending or which Aceragen intends to initiate. The foregoing includes, without limitation, actions, suits
8-K
EX-10.2
ACGN
Aceragen Inc
11 Jul 23
Other Events
5:06pm
, opposition, post-grant review, or investigation pending or, to the knowledge of Aceragen, threatened against Aceragen or any Affiliate of Aceragen … or investigation by Aceragen pending or which Aceragen intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations
DEFA14A
jjffwt0x62o
30 Sep 22
Additional proxy soliciting materials
4:18pm
8-K
EX-2.1
0dkmx6rf3 ksz6v53m
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.6
tkfo8b5ysy15lx2
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
x26d7pdu 6o
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.2
u51gid4 0uicwqt5
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.3
uvwjfhjfgg0asubo61ta
30 Sep 22
Entry into a Material Definitive Agreement
4:15pm
DEFA14A
EX-99.2
6oyefd0s0jv tbj
28 Sep 22
Additional proxy soliciting materials
4:59pm
8-K
EX-99.2
7mtcie8qbpd
28 Sep 22
Idera Pharmaceuticals Acquires Aceragen
4:29pm
8-K
EX-10.1
ck79tq1rsgxtdi uc7
18 May 21
Idera Pharmaceuticals Announces Corporate Updates
4:41pm
8-K
EX-99.1
vh3h4ppc8lj72bu37fo
13 Jan 21
Regulation FD Disclosure
8:05am
8-K
EX-4.1
rt2y6kcy99kmh
15 Jul 20
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
8:15am